



UROLOGY SERVICES INQUIRY

USI Ref: Notice 68 of 2022

Date of Notice: 23 August 2022

Note: S21 Notice No. 68 of 2022 can be found at WIT-82399 to WIT-82657.

Addendum No. 2 can be found at WIT-107564 to WIT-107623.

Annotated by the Urology Services Inquiry.

Addendum Witness Statement of: MR AIDAN O'BRIEN

I, Aidan O'Brien, wish to make the following amendments to my existing response, dated 2nd November 2022, to Section 21 Notice number 68 of 2022.

1. At Paragraph 135 I stated "*I did express concerns in relation to DARO in an email exchange in January/February 2009 primarily between Colette McCaul and me. [see AOB-07566-AOB-07567]*". This should be amended to state: "*I did express concerns in relation to DARO in an email exchange in January/February 200~~1~~⁹ primarily between Colette McCaul and me. [see AOB-07566-AOB-07567]*".
2. At Paragraph 544 I stated that "*At no point during my years of clinical practice as a consultant urologist within the Trust, from 1992 until 2020, was any concern raised with me in respect of the manner in which I prescribed Bicalutamide.*" At Paragraph 563 I stated that "*No concerns were ever raised during my tenure in respect of the use of Bicalutamide.*" At Paragraph 587, I stated that "*It could not be said that any issue in respect of my prescribing Bicalutamide recurred during my tenure, as no issue was ever raised with me in respect of my prescribing that medication during my tenure as a consultant urologist with the Trust.*"

Since submitting my Section 21 response dated 2 November 2022, I have come across an email sent to me by Dr Darren Mitchell, Consultant in Clinical Oncology at the Cancer Centre in Belfast (AOB-71990), on 20 November 2014, asking me to look into the case of a man who had been prescribed and remained



Urology Services Inquiry

on Bicalutamide since his diagnosis in 2012 until his referral for radical radiotherapy in 2014. The only identification detail given in the email was the patient's H&C number. The clinical details provided in that email indicate that he had a diagnosis of high grade, organ confined, prostatic carcinoma in 2012, that he had Bicalutamide 50 mg daily prescribed at some stage thereafter and on which he remained for one year prior to the dose being increased to 150 mg daily and subsequent referral for radical radiotherapy in 2014. I have not been able to find a reply to this email, and on the basis of the information available to me I am unable to confirm whether Dr Mitchell's request was responded to by email or other means.

Statement of Truth

I believe that the facts stated in this witness statement are true.

Personal Information redacted by the USI

Signed:

Date: 31 July 2023